Tiu V, Enache I, Panea C, Tiu C, Popescu B
Medicina (Kaunas). 2022; 58(3).
PMID: 35334554
PMC: 8949449.
DOI: 10.3390/medicina58030377.
Mazzucco M, Mannheim W, Shetty S, Linden J
Fluids Barriers CNS. 2022; 19(1):13.
PMID: 35135557
PMC: 8822708.
DOI: 10.1186/s12987-021-00299-4.
Paul A, Comabella M, Gandhi R
Cold Spring Harb Perspect Med. 2018; 9(3).
PMID: 29500303
PMC: 6396336.
DOI: 10.1101/cshperspect.a029058.
Dworkin J, Linn K, Oguz I, Fleishman G, Bakshi R, Nair G
AJNR Am J Neuroradiol. 2018; 39(4):626-633.
PMID: 29472300
PMC: 5895493.
DOI: 10.3174/ajnr.A5556.
Axisa P, Hafler D
Curr Opin Neurol. 2016; 29(3):345-53.
PMID: 27058221
PMC: 7882195.
DOI: 10.1097/WCO.0000000000000319.
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
Ottoboni L, Keenan B, Tamayo P, Kuchroo M, Mesirov J, Buckle G
Sci Transl Med. 2012; 4(153):153ra131.
PMID: 23019656
PMC: 3753678.
DOI: 10.1126/scitranslmed.3004186.
Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.
Deisenhammer F
CNS Drugs. 2009; 23(5):379-96.
PMID: 19453200
DOI: 10.2165/00023210-200923050-00003.
MRI: role in optimising treatment.
Traboulsee A
J Neurol. 2004; 251 Suppl 5:v36-v41.
PMID: 15549354
DOI: 10.1007/s00415-004-1506-9.
Multiple sclerosis.
Hafler D
J Clin Invest. 2004; 113(6):788-94.
PMID: 15067307
PMC: 362131.
DOI: 10.1172/JCI21357.
The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G.
Kocer B, Yildirim-Gurel S, Tali E, Irkec C, Isik S
Neuroradiology. 2004; 46(4):287-90.
PMID: 15007574
DOI: 10.1007/s00234-003-1088-8.
Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
Barkhof F, van Walderveen M
Philos Trans R Soc Lond B Biol Sci. 1999; 354(1390):1675-86.
PMID: 10603619
PMC: 1692677.
DOI: 10.1098/rstb.1999.0511.
Relevance of hypointense lesions on fast fluid-attenuated inversion recovery MR images as a marker of disease severity in cases of multiple sclerosis.
Rovaris M, Comi G, Rocca M, Cercignani M, Colombo B, Santuccio G
AJNR Am J Neuroradiol. 1999; 20(5):813-20.
PMID: 10369351
PMC: 7056128.
MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences.
Gawne-Cain M, ORiordan J, Coles A, Newell B, Thompson A, Miller D
J Neurol Neurosurg Psychiatry. 1998; 64(2):197-203.
PMID: 9489530
PMC: 2169948.
DOI: 10.1136/jnnp.64.2.197.
Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.
Koudriavtseva T, Thompson A, Fiorelli M, Gasperini C, Bastianello S, Bozzao A
J Neurol Neurosurg Psychiatry. 1997; 62(3):285-7.
PMID: 9069488
PMC: 1064162.
DOI: 10.1136/jnnp.62.3.285.
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E
J Neurol Neurosurg Psychiatry. 1996; 61(3):251-8.
PMID: 8795595
PMC: 486547.
DOI: 10.1136/jnnp.61.3.251.
Epidemiology of disabling neurological disease: how and why does disability occur?.
Wade D
J Neurol Neurosurg Psychiatry. 1996; 61(3):242-9.
PMID: 8795593
PMC: 486545.
DOI: 10.1136/jnnp.61.3.242.
The treatment of chronic progressive multiple sclerosis with cladribine.
Beutler E, Sipe J, Romine J, Koziol J, McMillan R, Zyroff J
Proc Natl Acad Sci U S A. 1996; 93(4):1716-20.
PMID: 8643695
PMC: 40008.
DOI: 10.1073/pnas.93.4.1716.
A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis.
Lai M, Hodgson T, Gawne-Cain M, Webb S, MacManus D, McDonald W
J Neurol Neurosurg Psychiatry. 1996; 60(3):339-41.
PMID: 8609517
PMC: 1073863.
DOI: 10.1136/jnnp.60.3.339.
Multiple sclerosis.
Lynch S, Rose J
Dis Mon. 1996; 42(1):1-55.
PMID: 8556963
PMC: 7130340.
DOI: 10.1016/s0011-5029(96)90012-7.